Nuvation Bio Secures $250M Funding to Accelerate Next-Gen Oncology Breakthroughs

Nuvation Bio is thrilled to announce an exciting funding milestone with a successful raise of $250,000,000 that will accelerate the company’s advanced oncology initiatives. Since its inception in 2018 by biopharma industry veteran David Hung, M.D.—who famously founded Medivation, Inc.—Nuvation Bio has been at the forefront of addressing some of the most challenging unmet needs in cancer treatment. With state-of-the-art research and innovative therapeutic strategies, the company is dedicated to transforming the lives of patients worldwide by developing differentiated and novel therapeutic candidates. The recent capital injection is set to bolster the company’s ambitious portfolio, which includes promising development candidates such as taletrectinib (targeting ROS1), safusidenib (designed for mIDH1), NUV-868 (focused on BET inhibition), and NUV-1511 (aimed at the DDC pathway). This crucial funding round underscores the confidence that investors have in Nuvation Bio’s visionary approach and robust plan to bring groundbreaking therapies to market in the field of oncology. With strategic offices in New York, San Francisco, and Shanghai, the company is uniquely positioned to leverage global networks of research talent and clinical expertise, ensuring that its advancements in cancer therapy can swiftly translate into tangible patient benefits. As Nuvation Bio embarks on this next phase of growth, the infusion of capital will not only facilitate further clinical development and expansion of its therapeutic pipeline, but also reinforce the company’s commitment to delivering best-in-class treatments for patients facing some of the most aggressive and resilient forms of cancer.